TABLE 3.
Changes in inflammatory cells
| Cell type | Sputum sample | HFA-BDP active | HFA-BDP placebo | DPI-BUD active | DPI-BUD placebo |
|---|---|---|---|---|---|
| Eosinophils | Early | −7.3 ± 1.7 | −0.4 ± 2.1 | −6.4 ± 2.1 | 1.9 ± 1.2 |
| Late | −4.3 ± 0.8 | 0.9 ± 1.5 | −3.5 ± 1.8 | −3.1 ± 1.9 | |
| Neutrophils | Early | 13.5 ± 6.0 | −11.4 ± 8.1 | 3.8 ± 4.9 | 0.2 ± 6.1 |
| Late | 7.1 ± 5.8 | −3.9 ± 5.9 | 1.8 ± 3.5 | 6.3 ± 5.9 | |
| Lymphocytes | Early | −0.5 ± 0.4 | 0.9 ± 0.7 | 0.7 ± 0.5 | 0.0 ± 0.5 |
| Late | −0.1 ± 0.5 | 0.1 ± 0.5 | 0.9 ± 0.6 | 1.4 ± 0.3 | |
| Macrophages | Early | −11.1 ± 4.8 | 3.7 ± 8.8 | −0.7 ± 6.0 | −2.6 ± 5.4 |
| Late | −7.7 ± 10.4 | 0.9 ± 3.9 | 0.5 ± 4.7 | 5.4 ± 4.9 |
Changes in the percentage of positive cells with respect to total cells. Values are given as means ± SEM. DPI-BUD Budesonide in a dry powder inhaler; HFA-BDP Hydrofluoroalkane formulation of beclomethasone dipropionate